Jan Burger

39PUBLICATIONS

153CO-AUTHORS

Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursOtorhinolaryngology

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (39)

Sort by Publication Date:

|Jun 27, 2026

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

|Mar 25, 2026

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

Alexandre Bazinet, Alessandra Ferrajoli, Nitin Jain

|Feb 12, 2026

Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.

Mahesh Swaminathan, Alessandra Ferrajoli, Philip A Thompson

|Dec 10, 2025

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi

|Jul 30, 2025

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.

Jan A Burger, Paul M Barr, Tadeusz Robak

|Feb 25, 2025

Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi

Pageof 7

Frequent Collaborators

13 joint publications

William Wierda

Nitin Jain

Zeev Estrov

Philip Thompson

Hagop M Kantarjian

Elias Jabbour

Naval G Daver

Naveen Pemmaraju

Gautam Borthakur

Koji Sasaki

Frequent Collaborators

13 joint publications

William Wierda

8 joint publications

Nitin Jain

8 joint publications

Zeev Estrov

7 joint publications

Philip Thompson